<DOC>
	<DOCNO>NCT01557452</DOCNO>
	<brief_summary>Givinostat expect exert clinically relevant therapeutic effect polyarticular JIA inhibition production/release pro-inflammatory cytokine , IL-1β , IL-6 TNFα , involve pathogenesis arthritic process .</brief_summary>
	<brief_title>An Open-Label Extension Dose Finding Study ( DSC/08/2357/36 ) Patients With Poly Juvenile Idiopathic Arthritis ( JIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>subject successfully complete previous Dose Finding Study fully compliant inclusion/exclusion criterion describe previous DSC/08/2357/36 patient fever relate JIA systemic feature JIA 12 month enter study active bacterial mycotic infection require antimicrobial treatment episode macrophage activation syndrome last 6 month baseline prolongation QT/QTc interval , use concomitant medication prolong QT/QTc interval history additional risk factor TdP . clinically significant cardiovascular disease clinically significant illness i.e . condition opinion Investigator place patient unacceptable risk adverse outcome he/she participate study psychiatric illness/social situation would limit compliance study medication protocol requirement inherit metabolic disease presence malignancy pregnancy lactation positive blood test HIV active EBV infection , active B and/or C hepatitis platelet count &lt; 100x10 ( 9 ) /L</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>JIA</keyword>
</DOC>